



## Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team

July 30, 2020

CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Antoine 'Tony' Awad to the position of Chief Operating Officer. As Chief Operating Officer, Tony will drive Synlogic's end to end development & manufacturing organization and supply chain as well as have broader corporate operations responsibilities, inclusive of laboratory operations, IT infrastructure, and the quality organization.

"At Synlogic, we are executing on our mission to bring the transformative potential of synthetic biology to medicine and continue to grow our leadership team to advance that mission," said Aoife Brennan, M.B. Ch.B., Synlogic's president and chief executive officer. "Tony's leadership has been instrumental in realizing a critical component of that mission – bringing Synthetic Biotic medicines from lab to the clinic and paving the way for potential future commercialization. This expanded role is both a recognition of his impact on Synlogic and a signal of the criticality of manufacturing capabilities to our future success."

"Thank you to Aoife and Synlogic for the trust and teamwork over the past two years," said Tony Awad, Synlogic's chief operating officer. "I am looking forward to continuing to advance the Synthetic Biotic platform and potentially providing new treatment options to patients with PKU, Enteric Hyperoxaluria, and other devastating diseases."

Tony joined Synlogic in December 2018 as Head of Technical Operations. He brings over 15 years of experience in the biotechnology and pharmaceutical industry with substantial experience in the development and manufacturing of novel therapeutics from pre-IND studies through global commercialization. Prior to joining Synlogic, Tony served as Senior Vice President of CMC and Operations at Abpro Therapeutics and L.E.A.F. Pharmaceuticals and served in roles of increasing responsibility at Ipsen Biosciences and Merrimack Pharmaceuticals. Tony is a graduate of Boston University and holds degree in biochemistry and molecular biology and conducted graduate research at Boston University School of Dental Medicine.

Synlogic also announced the appointment of Andrew Marsh as Head of Development Operations. Andrew brings over 15 years of experience across an array of therapeutic areas, including rare diseases and oncology, and has executed initial IND through registrational human clinical studies.

Prior to joining Synlogic he served as Ra Pharmaceuticals' Head of Clinical Development. Andrew is a graduate of Boston University and holds a degree in biomedical engineering. He will be responsible for Clinical Operations, Biometrics, and Clinical Bioanalytics, and will drive execution of clinical studies of Synthetic Biotic medicines, including SYN1618 for the potential treatment of PKU, SYN8802 for the potential treatment of enteric hyperoxaluria, and SYN1891 for the potential treatment of solid tumors in combination with checkpoint inhibitors.

### About Synlogic

Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.

### Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the expected timing of Synlogic's clinical trials and availability of clinical trial data; the timing and progress of our Phase 1 clinical trial of SYN1891 in patients with advanced solid tumors or lymphoma; and the potential benefits of SYN1891. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

[to-chief-operating-officer-and-additions-to-leadership-team-301102169.html](https://www.synlogictx.com/newsroom/2021/01/2021-01-14-to-chief-operating-officer-and-additions-to-leadership-team-301102169.html)

SOURCE Synlogic, Inc.

Media Contact: Caroline Rufo, Ph.D., MacDougall, Phone: 781-235-3060, Email: [cruf@macbiocom.com](mailto:cruf@macbiocom.com) | Investor Contact: Daniel Rosan, Synlogic, Inc., Phone: 617-207-5509, Email: [dan.rosan@synlogictx.com](mailto:dan.rosan@synlogictx.com)